Research & Clinical Trials
Contact: Diane Smith, CCRP at (585) 275-0404
A Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Midazolam Intranasal Spray (USL261) for the Treatment of Intermittent Bouts of Increased Seizure Activity in the Epilepsy Monitoring Unit (EMU) - Protocol Number: P261-301 – Subjects must be ≥ 12 years of age at Screening. Dr. Hughes is a sub-I on this study.
A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SAGE-547 Injection in the Treatment of Subjects with Super-Refractory Status Epilepticus - Subjects >2 years of age and older - PROTOCOL NUMBER: 547-SSE-301). Dr. Hughes is a sub-I on this study.
Contact: Amy Vierhile, PNP at (585) 275-4762
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE) - Enrolling 5 ½-16 year olds who are naïve to AEDs or weaned off and needed to be restarted. They need to have focal epilepsy and are randomized to receive either levetiracetam, oxcarbazepine or lamotrigine. There is cognitive testing at baseline, 3 months and 6 months. This is the first head to head comparison trial of 3 AEDS for focal epilepsy, to see if there is one that affects cognition less than the other two.
Open-Label, Single-Arm, Multicenter, Long-Term Study to evaluate safety and efficacy of brivaracetam used as adjunctive treatment in pediatric subjects with epilepsy. This study is for children ages 5-16 with focal seizures who are on at least one AED. They must have at least 1 seizure in the 3 weeks before the first visit and cannot have used Keppra within a month of the visit.